Biotech Values

[genisi]

$250 million cash payment upon certain U.S. approval of ABRAXANE® by FDA for NSCLC with progression-free survival claim in U.S. label

No PFS benefit for Abraxane in NSCLC so far. CELG hopes to find a sub-population in the final analysis:

Completed Interim Analysis of ABRAXANE(R) Phase III Study in Non-Small Cell Lung Cancer (NSCLC); Interim Analysis of Progression Free Survival (PFS) in the Intent-to-Treat Population, While Not Statistically Significant, Supports Submission of a Supplemental New Drug Application for the Treatment of Advanced NSCLC During the Second Half of 2011. Final Analysis, Including Subset Analyses, Expected to Be Completed and Presented During an Upcoming Medical Meeting.

http://classic.cnbc.com/id/41002737